In this Aug. 16, 2010 photo, patient Bob Svensson is hooked up to a blood infusion machine at the American Red Cross in Dedham, Mass., as he undergoes a $93,000 prostate cancer treatment. The Provenge therapy, approved in April, adds four months’ survival, on average, for men with incurable prostate tumors. Bob Svensson is honest about why he got it: insurance paid. “I would not spend that money,” because the benefit doesn’t seem worth it, says Svensson, 80, a former corporate finance officer from Bedford, Mass. (AP Photo/Elise Amendola)